Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice

Pharmacological Research

Volumn 64, Issue 1, 2011, Pages 68-79

  Mazzon, Emanuela ^a   Esposito, Emanuela ^a   Di Paola, Rosanna ^a   Impellizzeri, Daniela ^b   Bramanti, Placido ^a   Cuzzocrea, Salvatore ^a,b  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Apoptosis; Cytokine; Inflammation; MOF; NF B; Olprinone

Indexed keywords

3 NITROTYROSINE; FAS LIGAND; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LOPRINONE; MYELOPEROXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PADGEM PROTEIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MIGRATION INHIBITION; MOUSE; MULTIPLE ORGAN FAILURE; NITROSATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; AMYLASES; ANIMALS; APOPTOSIS; ASCITIC FLUID; ASPARTATE AMINOTRANSFERASES; BCL-2-ASSOCIATED X PROTEIN; BICARBONATES; BILIRUBIN; BLOOD GAS ANALYSIS; BODY WEIGHT; CELL COUNT; CREATININE; FAS LIGAND PROTEIN; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; KIDNEY; LIPASE; LIVER; LUNG; MALE; MICE; MICE, INBRED STRAINS; MULTIPLE ORGAN FAILURE; NITRATES; NITRITES; P-SELECTIN; PANCREAS; PHOSPHODIESTERASE 3 INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDONES; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; ZYMOSAN;

EID: 79957689782     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.12.010     Document Type: Article

References (40)

1. Shayevitz JR, Miller C, Johnson KJ, Rodriguez JL. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shock 1995;4:389-96.
2. Goris RJ, Boekholtz WK, van Bebber IP, Nuytinck JK, Schillings PH. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 1986;121:897-901. (Pubitemid 16039334)
3. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Annals of surgery 1992;216:117-34.
4. Cuzzocrea S, Costantino G, Mazzon E, Caputi AP. Protective effect of n-acetylcysteine on multiple organ failure induced by zymosan in the rat. Crit Care Med 1999;27:1524-32. (Pubitemid 29406943)
5. Volman TJ, Hendriks T, Goris RJ. Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome. Shock Augusta, GA 2005;23:291-7. (Pubitemid 40463620)
6. Cuzzocrea S, de Sarro G, Costantino G, Mazzon E, Laura R, Ciriaco E, et al. Role of interleukin-6 in a non-septic shock model induced by zymosan. Eur Cytokine Netw 1999;10:191-203. (Pubitemid 29332775)
7. Ward PA, Till GO, Kunkel R, Beauchamp C. Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest 1983;72:789-801. (Pubitemid 14211389)
8. Mizushige K, Ueda T, Yukiiri K, Suzuki H. Olprinone: a phosphodiesterase iii inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev 2002;20:163-74. (Pubitemid 35204766)
9. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase iii inhibitors: the role of protein kinase a and p38 mitogen-activated protein kinase. Circulation 2001;104:705-10. (Pubitemid 32738527)
10. Ueda T, Mizushige K, Yukiiri K, Nishiyama Y, Kohno M. The cerebrovascular dilatation effects of olprinone, a phosphodiesterase iii inhibitor, in comparison with acetazolamide - a pilot study. Clin Neurol Neurosurg 2004;106: 284-8. (Pubitemid 39024627)
11. Tajimi M, Ozaki H, Sato K, Karaki H. Effect of a novel inhibitor of cyclic amp phosphodiesterase, e-1020, on cytosolic Ca++ level and contraction in vascular smooth muscle. Naunyn-Schmiedeberg's Arch Pharmacol 1991;344:602-10.
12. Okuda K, Kudo H, Ohishi K, Kitano T, Imasaka H, Noguchi T. Effects of olprinone on il-6 and il-10 production during and after cardiac surgery. Masui 1997;46:1580-4. (Pubitemid 28030620)
13. Kanda M, Yasuda S, Goto Y, Sumida H, Baba T, Noguchi T, et al. Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure. AmJCardiol 1999;83(1274-1277):A1279.
14. Sadiq A, Tamura N, Yoshida M, Hoshiba Y, Kumagai A, Tanabe T, et al. Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone. Thromb Res 2003;111:357-61. (Pubitemid 38032902)
15. Esposito E, Mazzon E, Paterniti I, Impellizzeri D, Bramanti P, Cuzzocrea S. Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice. PLoS One 2010;5:e12170.
16. Koike T, Nadeen Qutab M, Tsuchida M, Takekubo M, Saito M, Hayashi J. Pretreatment with olp rinone hydrochloride, a phosphodiesterase iii inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulm Pharmacol Ther 2008;21:166-71.
17. Di Paola R, Mazzon E, Paterniti I, Impellizzeri D, Bramanti P, Cuzzocrea S. Olprinone, a pde3 inhibitor, modulates the inflammation associated with myocardial ischemia-reperfusion injury in rats. Eur J Pharmacol 2011;650:612-20.
18. Crisafulli C, Mazzon E, Galuppo M, Paterniti I, Caminiti R, Cuzzocrea S. Olprinone attenuates the development of ischemia/reperfusion injury of the gut. Intensive Care Med 2010;36:1235-47.
19. Cuzzocrea S, Mazzon E, Di Paola R, Patel NS, Genovese T, Muia C, et al. Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther 2004;311:1272-80. (Pubitemid 39612737)
20. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63-9. (Pubitemid 40228212)
21. Genovese T, Di Paola R, Catalano P, Li JH, Xu W, Massuda E, et al. Treatment with a novel poly(adp-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice. Crit Care Med 2004;32:1365-74. (Pubitemid 38738594)
22. Mahesh J, Daly J, Cheadle WG, Kotwal GJ. Elucidation of the early events contributing to zymosan-induced multiple organ dysfunction syndrome using mip-1alpha, c3 knockout, and c5-deficient mice. Shock 1999;12:340-9.
23. Omori K, Kotera J. Overview of pdes and their regulation. Circ Res 2007;100:309-27.
24. Van Riper DA, Weaver BA, Stull JT, Rembold CM. Myosin light chain kinase phosphorylation in swine carotid artery contraction and relaxation. Am J Physiol 1995;268:H2466-2475.
25. Fujikawa H, Kanno T, Nagata T, Nishizaki T. The phosphodiesterase iii inhibitor olprinone inhibits hippocampal glutamate release via a cgmp/pkg pathway. Neurosci Lett 2008;448:208-11.
26. Matsumoto S, Cho S, Tosaka S, Ureshino H, Maekawa T, Hara T, et al. Pharmacological preconditioning in type 2 diabetic rat hearts: The roles of mitochondrial atp-sensitive potassium channels and the phosphatidylinositol 3-kinase-akt pathway. Cardiovasc Drugs Ther 2009;23:263-70.
27. Anas C, Ozaki T, Maruyama S, Yamamoto T, Zu Gotoh M, Ono Y, et al. Effects of olprinone, a phosphodiesterase iii inhibitor, on ischemic acute renal failure. Int J Urol 2007;14:219-25. (Pubitemid 46423256)
28. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein nf-kappa b by a posttranslational mechanism. Cell 1986;47:921-8. (Pubitemid 17005065)
29. Rahman A, Anwar KN, Minhajuddin M, Bijli KM, Javaid K, True AL, et al. Camp targeting of p38 map kinase inhibits thrombin-induced NF-κB activation and icam-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004;287. L1017-24.
30. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C. Role of phosphodiesterase 3 in no/cgmp-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 2003;93:406-13. (Pubitemid 37100005)
31. Volman TJ, Hendriks T, Verhofstad AA, Kullberg BJ, Goris RJ. Improved survival of tnf-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Shock 2002;17:468-72.
32. Cuzzocrea S, Mazzon E, Dugo L, Barbera A, Centorrino T, Ciccolo A, et al. Inducible nitric oxide synthase knockout mice exhibit resistance to the multiple organ failure induced by zymosan. Shock 2001;16:51-8. (Pubitemid 33598188)
33. Salvemini D, Muscoli C, Riley DP, Cuzzocrea S. Superoxide dismutase mimetics. Pulmonary Pharmacol Therapeut 2002;15:439-47.
34. Cuzzocrea S, Rossi A, Pisano B, Di Paola R, Genovese T, Patel NS, et al. Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med 2003;29:2016-25. (Pubitemid 37487138)
35. Szabo C, Dawson VL. Role of poly(adp-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends PharmacolSci 1998;19:287-98. (Pubitemid 28358088)
36. Cuzzocrea S, Zingarelli B, Sautebin L, Rizzo A, Crisafulli C, Campo GM, et al. Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. Shock 1997;8:268-75. (Pubitemid 127654337)
37. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, et al. Death the fas way: regulation and pathophysiology of cd95 and its ligand. Pharmacol Therap 2000;88:333-47. (Pubitemid 32406057)
38. Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E, et al. The fas-fadd death domain complex structure unravels signalling by receptor clustering. Nature 2009;457:1019-22.
39. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6. (Pubitemid 28406817)
40. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19. (Pubitemid 23259742)